AR106940A1 - ANTI CLAUDINE ANTIBODIES AND METHODS OF USE - Google Patents
ANTI CLAUDINE ANTIBODIES AND METHODS OF USEInfo
- Publication number
- AR106940A1 AR106940A1 ARP160103710A ARP160103710A AR106940A1 AR 106940 A1 AR106940 A1 AR 106940A1 AR P160103710 A ARP160103710 A AR P160103710A AR P160103710 A ARP160103710 A AR P160103710A AR 106940 A1 AR106940 A1 AR 106940A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- established
- claudine
- antibodies
- methods
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 7: El conjugado de anticuerpo y fármaco de las reivindicaciones 1 ó 2 que comprende un anticuerpo anti-CLDN que comprende o compite por la unión a una proteína CLDN humana con un anticuerpo caracterizado porque comprende una región variable de cadena liviana (VL) establecida como la SEQ ID Nº 61 y una región variable de cadena pesada (VH) establecida como la SEQ ID Nº 63 (hSC27.1); o una VL establecida como la SEQ ID Nº 65 y una VH establecida como la SEQ ID Nº 67 (hSC27.22); o una VL establecida como la SEQ ID Nº 69 y una VH establecida como la SEQ ID Nº 71 (hSC27.108); o una VL establecida como la SEQ ID Nº 73 y una VH establecida como la SEQ ID Nº 75 (hSC27.204); o una VL establecida como la SEQ ID Nº 73 y una VH establecida como la SEQ ID Nº 77 (hSC27.204v2).Claim 7: The antibody and drug conjugate of claims 1 or 2 comprising an anti-CLDN antibody comprising or competing for binding to a human CLDN protein with an antibody characterized in that it comprises an established light chain variable region (VL) such as SEQ ID No. 61 and a heavy chain variable region (VH) established as SEQ ID No. 63 (hSC27.1); or a VL established as SEQ ID No. 65 and a VH established as SEQ ID No. 67 (hSC27.22); or a VL established as SEQ ID No. 69 and a VH established as SEQ ID No. 71 (hSC27.108); or a VL established as SEQ ID No. 73 and a VH established as SEQ ID No. 75 (hSC27.204); or a VL established as SEQ ID No. 73 and a VH established as SEQ ID No. 77 (hSC27.204v2).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263542P | 2015-12-04 | 2015-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106940A1 true AR106940A1 (en) | 2018-03-07 |
Family
ID=61768558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103710A AR106940A1 (en) | 2015-12-04 | 2016-12-02 | ANTI CLAUDINE ANTIBODIES AND METHODS OF USE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR106940A1 (en) |
-
2016
- 2016-12-02 AR ARP160103710A patent/AR106940A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001575A1 (en) | Anti-trem2 antibodies and related methods. | |
| CY1125260T1 (en) | TIGIT COMMITMENT FACTORS AND THEIR USES | |
| CL2016003346A1 (en) | Humanized anti-tau antibodies | |
| DOP2018000259A (en) | BISPECIFIC UNION PROTEINS THAT JOIN AN IMMUNOMODULATORY PROTEIN AND A TUMORAL ANTIGEN | |
| CO2019012210A2 (en) | Anti-trem2 antibodies and methods of using them | |
| EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
| CL2018003136A1 (en) | Specific binding proteins and uses thereof. | |
| CL2017000278A1 (en) | Bispecific t-cell activating antigen binding molecules | |
| CL2018001000A1 (en) | Antibodies and antibody conjugates and anti-egfr drug. | |
| AR102554A1 (en) | ANTI-CLDN ANTIGEN CHEMERIC RECEIVERS AND METHODS OF USE | |
| PE20240111A1 (en) | BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF | |
| MX2019000730A (en) | Multispecific antigen binding proteins and methods of use thereof. | |
| CL2017000545A1 (en) | Anti-her2 and immunoconjugate antibodies | |
| PE20161390A1 (en) | MULTI-SPECIFIC ANTIBODIES | |
| PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
| CU20160101A7 (en) | IMMUNOGLOBULINA WITH FAB IN TANDEM | |
| ECSP18096095A (en) | ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM | |
| CR20180013A (en) | ANTI-TAU ANTIBODIES AND METHODS OF USE. | |
| PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
| PE20170701A1 (en) | IMMUNOMODULATORS | |
| AU2016219350A8 (en) | Humanized anti-MUC1* antibodies | |
| MX2020004801A (en) | Bispecific fusion polypeptides and methods of use thereof. | |
| MX2017005977A (en) | Bispecific antibodies and methods of use in ophthalmology. | |
| PE20161210A1 (en) | ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE | |
| UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |